JAK2 and COVID-19: Ruxolitinib is under clinical investigation to evaluate COVID-19-associated lung injury [121], and another JAK2 inhibitor, nintedanib, is being evaluated for SARS-CoV-2-induced pulmonary fibrosis [122].